Patrick A. Flume

TitleEndowed Chair, Powers-Huggins Endowed Chair for Cystic Fibrosis
InstitutionMedical University of South Carolina
DepartmentPulmonary
AddressP.O. Box MSC 630
Clinical Science Bldg. - 96 Jonathan Lucas St.
Phone843-792-3167
Fax843-876-2057
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Patrick Flume joined the faculty of the Pulmonary and Critical Care Division at the Medical University of South Carolina in 1993. He is now a Professor of Medicine and Pediatrics, overseeing a rapidly growing Cystic Fibrosis Center. Though he continues to practice general pulmonary and critical care medicine, his primary interests are in CF and bronchiectasis, and chronic lung infections, including nontuberculous mycobacteria.

    The MUSC Cystic Fibrosis Center is the principal CF program in South Carolina. They provide state-of-the-art care to patients and families with CF; provide primary educator of clinicians and basic scientists in the field of CF; and perform basic and clinical research in the field of CF. Dr. Flume is the MUSC CF Center Director and has national recognition by the national and international CF community having served on the Cystic Fibrosis Foundation Center Committee, the Adult Care Consensus Committee, the Advisory Task Force on Adult Issues, the Professional Education Committee, and as co-chair for the Pulmonary Practice Guidelines Committee.

    Dr. Flume has an active clinical research program and heads the MUSC Research Nexus.
    Collapse keywords
    Cystic Fibrosis, Lung, Vision/ Eye, Drug Studies, Pediatrics, Pulmonary, Adolescents, Healthy Volunteer Studies, Infectious Diseases, Non-interventional, Breathing, Inflammation, Stage III

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Flume PA, Basavaraj A, Garcia B, Winthrop K, Di Mango E, Daley CL, Philley JV, Henkle E, O'Donnell AE, Metersky M. Towards development of evidence to inform recommendations for the evaluation and management of bronchiectasis. Respir Med. 2023 Mar 15; 107217. PMID: 36931575.
      Citations:    Fields:    Translation:Humans
    2. Hamidi B, Flume PA, Simpson KN, Alekseyenko AV. Not all phenotypes are created equal: covariates of success in e-phenotype specification. J Am Med Inform Assoc. 2023 01 18; 30(2):213-221. PMID: 36069977; PMCID: PMC9846689.
      Citations: 1     Fields:    
    3. Flume PA, Harris RS, Paz-Diaz H, Ahluwalia N, Higgins M, Campbell D, Berhane I, Shih JL, Sawicki G. Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial. J Cyst Fibros. 2022 Dec 27. PMID: 36581484.
      Citations:    Fields:    
    4. Collaco JM, Albon D, Ostrenga JS, Flume P, Schechter MS, Cromwell EA. Factors associated with receiving CF care and use of telehealth in 2020 among persons with Cystic Fibrosis in the United States. J Cyst Fibros. 2022 Dec 14. PMID: 36526554.
      Citations:    Fields:    
    5. Flume PA, Garcia BA, Wilson D, Steed L, Dorman SE, Winthrop K. Inhaled nitric oxide for adults with pulmonary non-tuberculous mycobacterial infection. Respir Med. 2023 01; 206:107069. PMID: 36493605.
      Citations:    Fields:    Translation:HumansCells
    6. Ross RE, Hart E, Williams ER, Gregory CM, Flume PA, Mingora CM, Woodbury ML, Ross RE, Hart E, Williams ER, Gregory CM, Flume PA, Mingora CM, Woodbury ML. Combined Aerobic Exercise and Virtual Reality-Based Upper Extremity Rehabilitation Intervention for Chronic Stroke: Feasibility and Preliminary Effects on Physical Function and Quality of Life. Arch Rehabil Res Clin Transl. 2023 Mar; 5(1):100244. PMID: 36968163; PMCID: PMC10036233.
      Citations:    
    7. Prickett MH, Flume PA, Sabadosa KA, Tran QT, Marshall BC, Prickett MH, Flume PA, Sabadosa KA, Tran QT, Marshall BC. Telehealth and CFTR modulators: Accelerating innovative models of cystic fibrosis care. J Cyst Fibros. 2023 Jan; 22(1):9-16. PMID: 35879227.
      Citations:    Fields:    Translation:HumansPHPublic Health
    8. Hite MA, Gaertner WB, Garcia B, Flume PA, Maxwell PJ, George VV, Curran T, Hite MA, Gaertner WB, Garcia B, Flume PA, Maxwell PJ, George VV, Curran T. Abdominal Surgical Procedures in Adult Patients With Cystic Fibrosis: What Are the Risks? Dis Colon Rectum. 2022 08 01; 65(8):e805-e815. PMID: 35030557; PMCID: PMC9259049.
      Citations:    
    9. VanDevanter DR, West NE, Sanders DB, Skalland M, Goss CH, Flume PA, Heltshe SL, VanDevanter DR, West NE, Sanders DB, Skalland M, Goss CH, Flume PA, Heltshe SL. Antipseudomonal treatment decisions during CF exacerbation management. J Cyst Fibros. 2022 09; 21(5):753-758. PMID: 35466039; PMCID: PMC9509480.
      Citations:    Fields:    Translation:HumansCells
    10. Szentpetery S, Foil K, Hendrix S, Gray S, Mingora C, Head B, Johnson D, Flume PA, Szentpetery S, Foil K, Hendrix S, Gray S, Mingora C, Head B, Johnson D, Flume PA. A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus. J Cyst Fibros. 2022 07; 21(4):721-724. PMID: 35422395.
      Citations: 6     Fields:    Translation:Humans
    11. Szentpetery S, Fernandez GS, Schechter MS, Jain R, Flume PA, Fink AK, Szentpetery S, Fernandez GS, Schechter MS, Jain R, Flume PA, Fink AK. Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry. J Cyst Fibros. 2022 09; 21(5):777-783. PMID: 35396178; PMCID: PMC9509402.
      Citations: 2     Fields:    Translation:Humans
    12. Gold LS, Hansen RN, Patrick DL, Tabah A, Heltshe SL, Flume PA, Goss CH, West NE, Sanders DB, VanDevanter DR, Kessler L, Gold LS, Hansen RN, Patrick DL, Tabah A, Heltshe SL, Flume PA, Goss CH, West NE, Sanders DB, VanDevanter DR, Kessler L. Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations. J Cyst Fibros. 2022 07; 21(4):594-599. PMID: 35300932; PMCID: PMC9329190.
      Citations:    
    13. Mingora CM, Garcia BA, Mange KC, Yuen DW, Ciesielska M, van Ingen J, Flume PA, Dorman SE, Mingora CM, Garcia BA, Mange KC, Yuen DW, Ciesielska M, van Ingen J, Flume PA, Dorman SE. Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion. BMC Infect Dis. 2022 Mar 12; 22(1):246. PMID: 35279081; PMCID: PMC8918293.
      Citations:    
    14. Flume PA, Flume PA. From the Editor's Desk. J Cyst Fibros. 2022 03; 21(2):197-198. PMID: 35337599; PMCID: PMC8938743.
      Citations:    
    15. Hendrix SJ, Flume PA, First ER, Stone AA, Van Buskirk M, Hendrix SJ, Flume PA, First ER, Stone AA, Van Buskirk M. Improvements in anthropometric measures and gastrointestinal tolerance in patients with cystic fibrosis by using a digestive enzyme cartridge with overnight enteral nutrition. Nutr Clin Pract. 2022 Apr; 37(2):344-350. PMID: 35199869; PMCID: PMC9415120.
      Citations:    
    16. VanDevanter DR, Heltshe SL, Skalland M, West NE, Sanders DB, Goss CH, Flume PA, VanDevanter DR, Heltshe SL, Skalland M, West NE, Sanders DB, Goss CH, Flume PA. C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response. J Cyst Fibros. 2022 07; 21(4):588-593. PMID: 34933824; PMCID: PMC9206040.
      Citations:    
    17. Flume PA, Saiman L, Marshall B, Flume PA, Saiman L, Marshall B. The Impact of COVID-19 in Cystic Fibrosis. Arch Bronconeumol. 2022 06; 58(6):466-468. PMID: 34934258; PMCID: PMC8679495.
      Citations:    
    18. Flume PA, Saiman L, Marshall B, Flume PA, Saiman L, Marshall B. The Impact of COVID-19 in Cystic Fibrosis. Arch Bronconeumol. 2021 Dec 17. PMID: 35312519.
      Citations:    
    19. Goss CH, Heltshe SL, West NE, Skalland M, Sanders DB, Jain R, Barto TL, Fogarty B, Marshall BC, VanDevanter DR, Flume PA, Goss CH, Heltshe SL, West NE, Skalland M, Sanders DB, Jain R, Barto TL, Fogarty B, Marshall BC, VanDevanter DR, Flume PA, STOP2 Investigators. A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. Am J Respir Crit Care Med. 2021 12 01; 204(11):1295-1305. PMID: 34469706; PMCID: PMC8786075.
      Citations:    
    20. Sanders DB, Khan U, Heltshe SL, Skalland M, West NE, VanDevanter DR, Goss CH, Flume PA, Sanders DB, Khan U, Heltshe SL, Skalland M, West NE, VanDevanter DR, Goss CH, Flume PA, STOP2 Investigators. Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation. J Cyst Fibros. 2022 07; 21(4):574-580. PMID: 34857494; PMCID: PMC9148375.
      Citations:    
    21. Elborn JS, Flume PA, Van Devanter DR, Procaccianti C, Elborn JS, Flume PA, Van Devanter DR, Procaccianti C. Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis. Future Microbiol. 2021 09; 16:1087-1104. PMID: 34384254.
      Citations:    
    22. Prevots DR, Marras TK, Wang P, Mange KC, Flume PA, Prevots DR, Marras TK, Wang P, Mange KC, Flume PA. Hospitalization Risk for Medicare Beneficiaries With Nontuberculous Mycobacterial Pulmonary Disease. Chest. 2021 12; 160(6):2042-2050. PMID: 34314672; PMCID: PMC8727849.
      Citations:    
    23. Garcia B, Wilmskoetter J, Grady A, Mingora C, Dorman S, Flume P, Garcia B, Wilmskoetter J, Grady A, Mingora C, Dorman S, Flume P. Chest Computed Tomography Features of Nontuberculous Mycobacterial Pulmonary Disease Versus Asymptomatic Colonization: A Cross-sectional Cohort Study. J Thorac Imaging. 2022 May 01; 37(3):140-145. PMID: 34292274.
      Citations:    
    24. Orr RK, Hoehn JL, Col NF, Sawicki GS, Van Brunt K, Booth J, Bailey E, Millar SJ, Konstan MW, Flume PA. Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. J Cyst Fibros. 2022 01; 21(1):96-103. PMID: 34289939; PMCID: PMC9588169.
      Citations:    
    25. Janneh AH, Kassir MF, Dwyer CJ, Chakraborty P, Pierce JS, Flume PA, Li H, Nadig SN, Mehrotra S, Ogretmen B, Janneh AH, Kassir MF, Dwyer CJ, Chakraborty P, Pierce JS, Flume PA, Li H, Nadig SN, Mehrotra S, Ogretmen B. Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic COVID-19 patients. Sci Rep. 2021 07 09; 11(1):14232. PMID: 34244584; PMCID: PMC8270895.
      Citations:    
    26. Winthrop KL, Flume PA, Thomson R, Mange KC, Yuen DW, Ciesielska M, Morimoto K, Ruoss SJ, Codecasa LR, Yim JJ, Marras TK, van Ingen J, Wallace RJ, Brown-Elliott BA, Coulter C, Griffith DE, Winthrop KL, Flume PA, Thomson R, Mange KC, Yuen DW, Ciesielska M, Morimoto K, Ruoss SJ, Codecasa LR, Yim JJ, Marras TK, van Ingen J, Wallace RJ, Brown-Elliott BA, Coulter C, Griffith DE. Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial. Ann Am Thorac Soc. 2021 07; 18(7):1147-1157. PMID: 33326356; PMCID: PMC8328368.
      Citations:    
    27. Mingora CM, Flume PA, Mingora CM, Flume PA. Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series. Chest. 2021 10; 160(4):1232-1240. PMID: 34147501; PMCID: PMC8727888.
      Citations:    
    28. Dwyer CJ, Cloud CA, Wang C, Heidt P, Chakraborty P, Duke TF, McGue S, Jeffcoat B, Dunne J, Johnson L, Choi S, Nahhas GJ, Gandy AS, Babic N, Nolte FS, Howe P, Ogretmen B, Gangaraju VK, Tomlinson S, Madden B, Bridges T, Flume PA, Wrangle J, Rubinstein MP, Baliga PK, Nadig SN, Mehrotra S, Dwyer CJ, Cloud CA, Wang C, Heidt P, Chakraborty P, Duke TF, McGue S, Jeffcoat B, Dunne J, Johnson L, Choi S, Nahhas GJ, Gandy AS, Babic N, Nolte FS, Howe P, Ogretmen B, Gangaraju VK, Tomlinson S, Madden B, Bridges T, Flume PA, Wrangle J, Rubinstein MP, Baliga PK, Nadig SN, Mehrotra S. Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients. iScience. 2021 Jun 25; 24(6):102489. PMID: 33969281; PMCID: PMC8087581.
      Citations:    
    29. Jayaweera D, Flume PA, Singer NG, Cohen MS, Lachiewicz AM, Cameron A, Kumar N, Thompson J, Cabrera A, Daudelin D, Shaker R, Bauer PR, Jayaweera D, Flume PA, Singer NG, Cohen MS, Lachiewicz AM, Cameron A, Kumar N, Thompson J, Cabrera A, Daudelin D, Shaker R, Bauer PR. Prioritizing studies of COVID-19 and lessons learned. J Clin Transl Sci. 2021 Apr 21; 5(1):e106. PMID: 34192060; PMCID: PMC8185424.
      Citations:    
    30. Griffith DE, Thomson R, Flume PA, Aksamit TR, Field SK, Addrizzo-Harris DJ, Morimoto K, Hoefsloot W, Mange KC, Yuen DW, Ciesielska M, Wallace RJ, van Ingen J, Brown-Elliott BA, Coulter C, Winthrop KL, Griffith DE, Thomson R, Flume PA, Aksamit TR, Field SK, Addrizzo-Harris DJ, Morimoto K, Hoefsloot W, Mange KC, Yuen DW, Ciesielska M, Wallace RJ, van Ingen J, Brown-Elliott BA, Coulter C, Winthrop KL, CONVERT Study Group. Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure. Chest. 2021 09; 160(3):831-842. PMID: 33887244.
      Citations:    
    31. Flume PA, Berbari EF, Viera L, Hess R, Higgins J, Armstrong J, Rice L, True L, Shaker R, Buse JB, Panettieri RA, Flume PA, Berbari EF, Viera L, Hess R, Higgins J, Armstrong J, Rice L, True L, Shaker R, Buse JB, Panettieri RA. Managing the risks and benefits of clinical research in response to a pandemic. J Clin Transl Sci. 2021; 5(1):e105. PMID: 35757679; PMCID: PMC9201876.
      Citations: 1     
    32. Flume PA, Amelina E, Daines CL, Charlton B, Leadbetter J, Guasconi A, Aitken ML, Flume PA, Amelina E, Daines CL, Charlton B, Leadbetter J, Guasconi A, Aitken ML. Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study. J Cyst Fibros. 2021 11; 20(6):1003-1009. PMID: 33715994.
      Citations:    
    33. Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE, Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE, VX14-661-110 study group. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021 07; 9(7):733-746. PMID: 33581080.
      Citations:    
    34. Flume PA, Castellani C, Davies J, Flume PA, Castellani C, Davies J. JCF Year in Review. J Cyst Fibros. 2021 01; 20(1):1-2. PMID: 33526211; PMCID: PMC7846232.
      Citations:    
    35. Harruff EE, Kil J, Ortiz MGT, Dorgan D, Jain R, Poth EA, Fifer RC, Kim YJM, Shoup AG, Flume PA, Harruff EE, Kil J, Ortiz MGT, Dorgan D, Jain R, Poth EA, Fifer RC, Kim YJM, Shoup AG, Flume PA. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment. J Cyst Fibros. 2021 03; 20(2):288-294. PMID: 33341407.
      Citations:    
    36. Desjardins M, Halstead L, Simpson A, Flume P, Bonilha HS, Desjardins M, Halstead L, Simpson A, Flume P, Bonilha HS. Voice and Respiratory Characteristics of Men and Women Seeking Treatment for Presbyphonia. J Voice. 2022 Sep; 36(5):673-684. PMID: 33172730.
      Citations:    
    37. Ng C, Nadig T, Smyth AR, Flume P, Ng C, Nadig T, Smyth AR, Flume P. Treatment of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2020 11; 26(6):679-684. PMID: 32890021; PMCID: PMC7958864.
      Citations:    
    38. Chmiel JF, Flume P, Downey DG, Dozor AJ, Colombo C, Mazurek H, Sapiejka E, Rachel M, Constantine S, Conley B, Dgetluck N, Dinh Q, White B, Elborn JS, Chmiel JF, Flume P, Downey DG, Dozor AJ, Colombo C, Mazurek H, Sapiejka E, Rachel M, Constantine S, Conley B, Dgetluck N, Dinh Q, White B, Elborn JS, Lenabasum JBT101-CF-001 Study Group. Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. J Cyst Fibros. 2021 01; 20(1):78-85. PMID: 33011099.
      Citations:    
    39. Flume PA, Griffith DE, Chalmers JD, Daley CL, Olivier K, O'Donnell A, Aksamit T, Kasperbauer S, Leitman A, Winthrop KL, Flume PA, Griffith DE, Chalmers JD, Daley CL, Olivier K, O'Donnell A, Aksamit T, Kasperbauer S, Leitman A, Winthrop KL. Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians' Interpretation of a US Food and Drug Administration Workshop. Chest. 2021 02; 159(2):537-543. PMID: 32853648; PMCID: PMC8039007.
      Citations:    
    40. Orr RK, Hoehn JL, Col NF, VanDevanter DR, Heltshe SL, Sanders DB, West NE, Skalland M, Flume PA, Goss CH, STOP-OB Study. Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment. J Cyst Fibros. 2021 01; 20(1):36-38. PMID: 32800708; PMCID: PMC8298137.
      Citations:    
    41. Desjardins M, Halstead L, Simpson A, Flume P, Bonilha HS, Desjardins M, Halstead L, Simpson A, Flume P, Bonilha HS. Respiratory Muscle Strength Training to Improve Vocal Function in Patients with Presbyphonia. J Voice. 2022 May; 36(3):344-360. PMID: 32680804.
      Citations:    
    42. Desjardins M, Halstead L, Simpson A, Flume P, Bonilha HS, Desjardins M, Halstead L, Simpson A, Flume P, Bonilha HS. The Impact of Respiratory Function on Voice in Patients with Presbyphonia. J Voice. 2022 Mar; 36(2):256-271. PMID: 32641221.
      Citations:    
    43. Flume P, Castellani C, Flume P, Castellani C. JCF Year in Review. J Cyst Fibros. 2020 07; 19(4):505-506. PMID: 32593371; PMCID: PMC7314455.
      Citations:    
    44. Bullington W, Hempstead S, Smyth AR, Drevinek P, Saiman L, Waters VJ, Bell SC, VanDevanter DR, Flume PA, Elborn S, Muhlebach MS, Bullington W, Hempstead S, Smyth AR, Drevinek P, Saiman L, Waters VJ, Bell SC, VanDevanter DR, Flume PA, Elborn S, Muhlebach MS, Antimicrobial Resistance International Working Group in Cystic Fibrosis. Antimicrobial resistance: Concerns of healthcare providers and people with CF. J Cyst Fibros. 2021 05; 20(3):407-412. PMID: 32563724.
      Citations:    
    45. Mayer-Hamblett N, van Koningsbruggen-Rietschel S, Nichols DP, VanDevanter DR, Davies JC, Lee T, Durmowicz AG, Ratjen F, Konstan MW, Pearson K, Bell SC, Clancy JP, Taylor-Cousar JL, De Boeck K, Donaldson SH, Downey DG, Flume PA, Drevinek P, Goss CH, Fajac I, Magaret AS, Quon BS, Singleton SM, VanDalfsen JM, Retsch-Bogart GZ, Mayer-Hamblett N, van Koningsbruggen-Rietschel S, Nichols DP, VanDevanter DR, Davies JC, Lee T, Durmowicz AG, Ratjen F, Konstan MW, Pearson K, Bell SC, Clancy JP, Taylor-Cousar JL, De Boeck K, Donaldson SH, Downey DG, Flume PA, Drevinek P, Goss CH, Fajac I, Magaret AS, Quon BS, Singleton SM, VanDalfsen JM, Retsch-Bogart GZ. Building global development strategies for cf therapeutics during a transitional cftr modulator era. J Cyst Fibros. 2020 09; 19(5):677-687. PMID: 32522463; PMCID: PMC7492419.
      Citations:    
    46. Flume PA, VanDevanter DR, Flume PA, VanDevanter DR. Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes. Eur Respir J. 2020 04; 55(4). PMID: 32245773.
      Citations:    
    47. Bell SC, Flume PA, Castellani C, Bell SC, Flume PA, Castellani C. Seven P's of publication practices. J Cyst Fibros. 2020 05; 19(3):333-335. PMID: 32245683.
      Citations:    
    48. Snider SH, Flume PA, Gentilin SL, Lesch WA, Sampson RR, Sonne SC, Snider SH, Flume PA, Gentilin SL, Lesch WA, Sampson RR, Sonne SC. Overcoming non-compliance with clinical trial registration and results reporting: One Institution's approach. Contemp Clin Trials Commun. 2020 Jun; 18:100557. PMID: 32258818; PMCID: PMC7118290.
      Citations:    
    49. Orr RK, Hoehn JL, Col NF, Low D, Wilson DA, Flume PA. Screening practices for nontuberculous mycobacteria at US cystic fibrosis centers. J Cyst Fibros. 2020 07; 19(4):569-574. PMID: 32178969.
      Citations:    
    50. Flume P, Bell SC, Castellani C, Flume P, Bell SC, Castellani C. Pursuit of Equity. J Cyst Fibros. 2020 03; 19(2):171. PMID: 32527495.
      Citations:    
    51. Orr RK, Hoehn JL, Col NF, Cogen JD, Kahl BC, Maples H, McColley SA, Roberts JA, Winthrop KL, Morris AM, Holmes A, Flume PA, VanDevanter DR, Waters V, Muhlebach MS, Elborn JS, Saiman L, Bell SC, Antimicrobial Resistance International Working Group in Cystic Fibrosis. Finding the relevance of antimicrobial stewardship for cystic fibrosis. J Cyst Fibros. 2020 07; 19(4):511-520. PMID: 32122785.
      Citations:    
    52. Shteinberg M, Flume PA, Chalmers JD, Shteinberg M, Flume PA, Chalmers JD. Is bronchiectasis really a disease? Eur Respir Rev. 2020 Mar 31; 29(155). PMID: 31996354; PMCID: PMC9488738.
      Citations:    
    53. Ponce MC, Svendsen E, Steed L, Flume PA, Ponce MC, Svendsen E, Steed L, Flume PA. Impact of a Reduction in Susceptibility Testing for Pseudomonas aeruginosa in a Cystic Fibrosis Program. Am J Respir Crit Care Med. 2020 01 01; 201(1):114-116. PMID: 31469583.
      Citations:    
    54. Flume PA, Goss CH, VanDevanter D, Flume PA, Goss CH, VanDevanter D. Cystic Fibrosis: Advances in Understanding and Treatment. Semin Respir Crit Care Med. 2019 12; 40(6):699-700. PMID: 31887767.
      Citations:    
    55. Bell SC, Castellani C, Flume PA, Bell SC, Castellani C, Flume PA. Disruption in research publishing - the open access revolution. J Cyst Fibros. 2019 11; 18(6):747-749. PMID: 31836188.
      Citations:    
    56. Zemanick E, Burgel PR, Taccetti G, Holmes A, Ratjen F, Byrnes CA, Waters VJ, Bell SC, VanDevanter DR, Stuart Elborn J, Flume PA, Zemanick E, Burgel PR, Taccetti G, Holmes A, Ratjen F, Byrnes CA, Waters VJ, Bell SC, VanDevanter DR, Stuart Elborn J, Flume PA, Antimicrobial Resistance International Working Group in Cystic Fibrosis. Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. J Cyst Fibros. 2020 05; 19(3):370-375. PMID: 31680041.
      Citations:    
    57. Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Gilligan P, Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Gilligan P, Antimicrobial Resistance International Working Group in Cystic Fibrosis. Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clin Infect Dis. 2019 10 30; 69(10):1812-1816. PMID: 31056660.
      Citations:    
    58. Garcia B, Flume PA, Garcia B, Flume PA. Pulmonary Complications of Cystic Fibrosis. Semin Respir Crit Care Med. 2019 12; 40(6):804-809. PMID: 31659729.
      Citations:    
    59. Konstan MW, Flume PA, Konstan MW, Flume PA. Clinical care for cystic fibrosis: preparing for the future now. Lancet Respir Med. 2020 01; 8(1):10-12. PMID: 31570320.
      Citations:    
    60. Orr RK, Hoehn JL, Col NF, Sanders DB, Ostrenga JS, Rosenfeld M, Fink AK, Schechter MS, Sawicki GS, Flume PA, Morgan WJ. Predictors of pulmonary exacerbation treatment in cystic fibrosis. J Cyst Fibros. 2020 05; 19(3):407-414. PMID: 31257102; PMCID: PMC6940539.
      Citations:    
    61. Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J, Harris RS, Haseltine E, Stiles D, Li C, Ahluwalia N, Zhou H, Owen CA, Sawicki G, Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J, Harris RS, Haseltine E, Stiles D, Li C, Ahluwalia N, Zhou H, Owen CA, Sawicki G, VX15-661-113 Investigator Group. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11?years with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):708-713. PMID: 31253540.
      Citations:    
    62. Flume PA, Chalmers JD, Olivier KN, Flume PA, Chalmers JD, Olivier KN. Rheumatoid arthritis-associated bronchiectasis - Authors' reply. Lancet. 2019 05 18; 393(10185):2036. PMID: 31106746.
      Citations:    
    63. Nichols DP, Durmowicz AG, Field A, Flume PA, VanDevanter DR, Mayer-Hamblett N, Nichols DP, Durmowicz AG, Field A, Flume PA, VanDevanter DR, Mayer-Hamblett N. Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities. Ann Am Thorac Soc. 2019 05; 16(5):534-539. PMID: 30658043; PMCID: PMC6491060.
      Citations:    
    64. Orr RK, Hoehn JL, Col NF, Somayaji R, Parkins MD, Shah A, Martiniano SL, Tunney MM, Kahle JS, Waters VJ, Elborn JS, Bell SC, Flume PA, VanDevanter DR, Antimicrobial Resistance in Cystic Fibrosis InternationalWorking Group. Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. J Cyst Fibros. 2019 03; 18(2):236-243. PMID: 30709744.
      Citations:    
    65. Flume PA, Flume PA. The study of CFTR modulators in the very young. Lancet Respir Med. 2019 04; 7(4):287-289. PMID: 30686766.
      Citations:    
    66. Bell SC, Castellani C, Flume PA, Bell SC, Castellani C, Flume PA. JCF - progress in 2018. J Cyst Fibros. 2019 01; 18(1):1-5. PMID: 30665544.
      Citations:    
    67. Flume PA, Suthoff ED, Kosinski M, Marigowda G, Quittner AL, Flume PA, Suthoff ED, Kosinski M, Marigowda G, Quittner AL. Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):737-742. PMID: 30587335.
      Citations:    
    68. Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ, van Ingen J, Coulter C, Nezamis J, Winthrop KL, Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ, van Ingen J, Coulter C, Nezamis J, Winthrop KL, CONVERT Study Group. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018 12 15; 198(12):1559-1569. PMID: 30216086.
      Citations:    
    69. Szentpetery S, Flume PA, Szentpetery S, Flume PA. Optimizing outcomes of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2018 11; 24(6):606-611. PMID: 30124523.
      Citations:    
    70. Flume PA, Waters VJ, Bell SC, Van Devanter DR, Stuart Elborn J, Flume PA, Waters VJ, Bell SC, Van Devanter DR, Stuart Elborn J, Antimicrobial Resistance in Cystic Fibrosis International Working Group. Antimicrobial resistance in cystic fibrosis: Does it matter? J Cyst Fibros. 2018 11; 17(6):687-689. PMID: 30270113.
      Citations:    
    71. Kidd TJ, Canton R, Ekkelenkamp M, Johansen HK, Gilligan P, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Waters VJ, Kidd TJ, Canton R, Ekkelenkamp M, Johansen HK, Gilligan P, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, Waters VJ, Antimicrobial Resistance in Cystic Fibrosis International Working Group. Defining antimicrobial resistance in cystic fibrosis. J Cyst Fibros. 2018 11; 17(6):696-704. PMID: 30266518.
      Citations:    
    72. Flume PA, Chalmers JD, Olivier KN, Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018 09 08; 392(10150):880-890. PMID: 30215383; PMCID: PMC6173801.
      Citations:    
    73. Gilligan PH, Downey DG, Elborn JS, Flume PA, Funk S, Gilpin D, Kidd TJ, McCaughan J, Millar BC, Murphy PG, Rendall JC, Tunney MM, Moore JE, Gilligan PH, Downey DG, Elborn JS, Flume PA, Funk S, Gilpin D, Kidd TJ, McCaughan J, Millar BC, Murphy PG, Rendall JC, Tunney MM, Moore JE. "Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis. J Clin Microbiol. 2018 09; 56(9). PMID: 29875191; PMCID: PMC6113473.
      Citations:    
    74. Flume PA, Winthrop KL, Flume PA, Winthrop KL. Mycobacterial Disease: Evolving Concepts. Semin Respir Crit Care Med. 2018 Jun; 39(3):269. PMID: 30071542.
      Citations:    
    75. Furukawa BS, Flume PA, Furukawa BS, Flume PA. Nontuberculous Mycobacteria in Cystic Fibrosis. Semin Respir Crit Care Med. 2018 Jun; 39(3):383-391. PMID: 30071553.
      Citations:    
    76. Jennings MT, Flume PA, Jennings MT, Flume PA. Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies. Ann Am Thorac Soc. 2018 08; 15(8):897-902. PMID: 29812963; PMCID: PMC6322038.
      Citations:    
    77. Forrester JB, Steed LL, Santevecchi BA, Flume P, Palmer-Long GE, Bosso JA, Forrester JB, Steed LL, Santevecchi BA, Flume P, Palmer-Long GE, Bosso JA. In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates. Open Forum Infect Dis. 2018 Jul; 5(7):ofy158. PMID: 30046642; PMCID: PMC6055570.
      Citations:    
    78. Goss CH, Somayaji R, Flume PA, Goss CH, Somayaji R, Flume PA. Benefits of set length antibiotic treatment for pulmonary exacerbations. Lancet Respir Med. 2018 08; 6(8):575-577. PMID: 29960882; PMCID: PMC6633903.
      Citations:    
    79. West NE, Flume PA, West NE, Flume PA. Unmet needs in cystic fibrosis: the next steps in improving outcomes. Expert Rev Respir Med. 2018 07; 12(7):585-593. PMID: 29855230; PMCID: PMC6300137.
      Citations:    
    80. Bell L, Gentilin S, Sonne S, Mauney T, Flume P, Bell L, Gentilin S, Sonne S, Mauney T, Flume P. Providing Restricted Access to an Electronic Medical Record for Research Monitoring. Clin Res (Alex). 2018; 32(3). PMID: 30613763; PMCID: PMC6317372.
      Citations:    
    81. Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodková P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P, Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodkov? P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018 03; 17(2):153-178. PMID: 29506920.
      Citations:    
    82. Brown KL, Flume PA, Brown KL, Flume PA. Pediatric and Adult Recommendations Vary for Sibling Testing in Cystic Fibrosis. J Genet Couns. 2018 09; 27(5):1049-1054. PMID: 29429040.
      Citations:    
    83. Sonne S, Gentilin S, Sampson RR, Bell L, Mauney T, Young S, Bright K, Flume P, Sonne S, Gentilin S, Sampson RR, Bell L, Mauney T, Young S, Bright K, Flume P. Response to Commentary: Regulatory Support Improves Subsequent IRB Approval Rates in Studies Initially Deemed Not Ready for Review-A CTSA Institution's Experience. J Empir Res Hum Res Ethics. 2018 04; 13(2):148. PMID: 29345186.
      Citations:    
    84. Sonne S, Gentilin S, Sampson RR, Bell L, Mauney T, Young S, Bright K, Flume P, Sonne S, Gentilin S, Sampson RR, Bell L, Mauney T, Young S, Bright K, Flume P. Regulatory Support Improves Subsequent IRB Approval Rates in Studies Initially Deemed Not Ready for Review: A CTSA Institution's Experience. J Empir Res Hum Res Ethics. 2018 04; 13(2):139-144. PMID: 29345179; PMCID: PMC6309298.
      Citations:    
    85. Heltshe SL, West NE, VanDevanter DR, Sanders DB, Beckett VV, Flume PA, Goss CH, Heltshe SL, West NE, VanDevanter DR, Sanders DB, Beckett VV, Flume PA, Goss CH, STOP Study Group. Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF. Contemp Clin Trials. 2018 01; 64:35-40. PMID: 29170074; PMCID: PMC5742044.
      Citations:    
    86. Orr RK, Hoehn JL, Col NF, Bell SC, Castellani C, Flume PA. Learning's from the Editors Desk - 2017. J Cyst Fibros. 2017 11; 16(6):645-646. PMID: 29150008.
      Citations:    
    87. Orr RK, Hoehn JL, Col NF, Flume PA, Wainwright CE, Elizabeth Tullis D, Rodriguez S, Niknian M, Higgins M, Davies JC, Wagener JS. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. J Cyst Fibros. 2018 01; 17(1):83-88. PMID: 28651844.
      Citations:    
    88. Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, Chalmers JD, De Soyza A, Dimakou K, Elborn JS, Feldman C, Flume P, Goeminne PC, Loebinger MR, Menendez R, Morgan L, Murris M, Polverino E, Quittner A, Ringshausen FC, Tino G, Torres A, Vendrell M, Welte T, Wilson R, Wong C, O'Donnell A, Aksamit T, Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, Chalmers JD, De Soyza A, Dimakou K, Elborn JS, Feldman C, Flume P, Goeminne PC, Loebinger MR, Menendez R, Morgan L, Murris M, Polverino E, Quittner A, Ringshausen FC, Tino G, Torres A, Vendrell M, Welte T, Wilson R, Wong C, O'Donnell A, Aksamit T, EMBARC/BRR definitions working group. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017 06; 49(6). PMID: 28596426.
      Citations:    
    89. West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA, West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA, STOP investigators. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. J Cyst Fibros. 2017 Sep; 16(5):600-606. PMID: 28457954; PMCID: PMC6581038.
      Citations:    
    90. Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH, Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH, STOP Study Group. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2017 Sep; 16(5):592-599. PMID: 28460885; PMCID: PMC5582015.
      Citations:    
    91. VanDevanter DR, Heltshe SL, Spahr J, Beckett VV, Daines CL, Dasenbrook EC, Gibson RL, Raksha J, Sanders DB, Goss CH, Flume PA, VanDevanter DR, Heltshe SL, Spahr J, Beckett VV, Daines CL, Dasenbrook EC, Gibson RL, Raksha J, Sanders DB, Goss CH, Flume PA, STOP Study Group. Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis. J Cyst Fibros. 2017 09; 16(5):607-615. PMID: 28438499; PMCID: PMC6581041.
      Citations:    
    92. Olivier KN, Griffith DE, Eagle G, McGinnis JP, Micioni L, Liu K, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume PA, Dorgan D, Salathe M, Brown-Elliott BA, Gupta R, Wallace RJ, Olivier KN, Griffith DE, Eagle G, McGinnis JP, Micioni L, Liu K, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume PA, Dorgan D, Salathe M, Brown-Elliott BA, Gupta R, Wallace RJ. Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Am J Respir Crit Care Med. 2017 03 15; 195(6):814-823. PMID: 27748623; PMCID: PMC5363966.
      Citations:    
    93. Flume PA, VanDevanter DR, Flume PA, VanDevanter DR. The Cystic Fibrosis Survival Gap: Why Do Canadians Fare Better Than Americans? Ann Intern Med. 2017 04 18; 166(8):599-600. PMID: 28289748.
      Citations:    
    94. Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, Taylor-Cousar JL, Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, Taylor-Cousar JL. Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017 May; 16(3):371-379. PMID: 28209466.
      Citations:    
    95. Orr RK, Hoehn JL, Col NF, Flume PA, VanDevanter DR. The challenges of maintaining momentum in CF drug development and approval - Commentary. J Cyst Fibros. 2017 03; 16(2):170-171. PMID: 28179070.
      Citations:    
    96. Bell SC, Flume PA, Bell SC, Flume PA. Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough? Thorax. 2017 04; 72(4):297-299. PMID: 28077615.
      Citations:    
    97. Elborn JS, Davies J, Mall MA, Flume PA, Plant B, Elborn JS, Davies J, Mall MA, Flume PA, Plant B. Current strategies for the long-term assessment, monitoring, and management of cystic fibrosis patients treated with CFTR modulator therapy. J Cyst Fibros. 2017 01; 16(1):163-164. PMID: 27986495.
      Citations:    
    98. Barry PJ, Flume PA, Barry PJ, Flume PA. Bronchodilators in cystic fibrosis: a critical analysis. Expert Rev Respir Med. 2017 01; 11(1):13-20. PMID: 27718752.
      Citations:    
    99. Flume PA, VanDevanter DR, Flume PA, VanDevanter DR. Efficacy measures for clinical trials: A review series. J Cyst Fibros. 2016 07; 15(4):415. PMID: 27316664.
      Citations:    
    100. Flume PA, Clancy JP, Retsch-Bogart GZ, Tullis DE, Bresnik M, Derchak PA, Lewis SA, Ramsey BW, Flume PA, Clancy JP, Retsch-Bogart GZ, Tullis DE, Bresnik M, Derchak PA, Lewis SA, Ramsey BW. Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):809-815. PMID: 27233377.
      Citations:    
    101. Thompson V, Mayer-Hamblett N, Kloster M, Bilton D, Flume PA, Thompson V, Mayer-Hamblett N, Kloster M, Bilton D, Flume PA. Corrigendum to "Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study" [J Cyst Fibros (2015) 632-638]. J Cyst Fibros. 2016 Sep; 15(5):e54-e55. PMID: 27211571.
      Citations:    
    102. Raja TH, Flume PA, Raja TH, Flume PA. Adults with cystic fibrosis in Portugal: A first step towards improvement. Rev Port Pneumol (2006). 2016 May-Jun; 22(3):139-40. PMID: 27256624.
      Citations:    
    103. Orr RK, Hoehn JL, Col NF, VanDevanter DR, Flume PA, Morris N, Konstan MW. Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):783-790. PMID: 27139161; PMCID: PMC5086308.
      Citations:    
    104. Nadig TR, Flume PA, Nadig TR, Flume PA. Aerosolized Antibiotics for Patients with Bronchiectasis. Am J Respir Crit Care Med. 2016 Apr 01; 193(7):808-10. PMID: 27035784.
      Citations:    
    105. Flume PA, Flume PA. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):139-40. PMID: 27062882.
      Citations:    
    106. Elborn JS, Flume PA, Cohen F, Loutit J, VanDevanter DR, Elborn JS, Flume PA, Cohen F, Loutit J, VanDevanter DR. Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. J Cyst Fibros. 2016 09; 15(5):634-40. PMID: 26935334.
      Citations:    
    107. Orr RK, Hoehn JL, Col NF, Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE, Elborn JS. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros. 2016 07; 15(4):495-502. PMID: 26852040.
      Citations:    
    108. Gruber JD, Chen W, Parnham S, Beauchesne K, Moeller P, Flume PA, Zhang YM, Gruber JD, Chen W, Parnham S, Beauchesne K, Moeller P, Flume PA, Zhang YM. The role of 2,4-dihydroxyquinoline (DHQ) in Pseudomonas aeruginosa pathogenicity. PeerJ. 2016; 4:e1495. PMID: 26788419; PMCID: PMC4715436.
      Citations:    
    109. Konstan MW, Flume PA, Galeva I, Wan R, Debonnett LM, Maykut RJ, Angyalosi G, Konstan MW, Flume PA, Galeva I, Wan R, Debonnett LM, Maykut RJ, Angyalosi G. One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2016 Apr; 51(4):372-8. PMID: 26709158.
      Citations:    
    110. Morgan WJ, VanDevanter DR, Pasta DJ, Foreman AJ, Wagener JS, Konstan MW, Morgan WJ, VanDevanter DR, Pasta DJ, Foreman AJ, Wagener JS, Konstan MW, Scientific Advisory Group, Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis. Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. J Pediatr. 2016 Feb; 169:116-21.e2. PMID: 26388208.
      Citations:    
    111. Sanders DB, Fink A, Mayer-Hamblett N, Schechter MS, Sawicki GS, Rosenfeld M, Flume PA, Morgan WJ, Sanders DB, Fink A, Mayer-Hamblett N, Schechter MS, Sawicki GS, Rosenfeld M, Flume PA, Morgan WJ. Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. J Pediatr. 2015 Nov; 167(5):1081-8.e1. PMID: 26340874; PMCID: PMC5017309.
      Citations:    
    112. Gaggar A, Chen J, Chmiel JF, Dorkin HL, Flume PA, Griffin R, Nichols D, Donaldson SH, Gaggar A, Chen J, Chmiel JF, Dorkin HL, Flume PA, Griffin R, Nichols D, Donaldson SH. Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):227-33. PMID: 26321218; PMCID: PMC4993024.
      Citations:    
    113. Hurley MN, Prayle AP, Flume P, Hurley MN, Prayle AP, Flume P. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Cochrane Database Syst Rev. 2015 Jul 30; (7):CD009730. PMID: 26226131; PMCID: PMC6481905.
      Citations:    
    114. Hurley MN, Prayle AP, Flume P, Hurley MN, review co-authors, Prayle AP, Flume P. Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Paediatr Respir Rev. 2015 Sep; 16(4):246-8. PMID: 26298057.
      Citations:    
    115. Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M, Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M, VX11-770-110 (KONDUCT) Study Group. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015 Jul; 3(7):524-33. PMID: 26070913; PMCID: PMC4641035.
      Citations:    
    116. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP, Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP, TRAFFIC Study Group, TRANSPORT Study Group. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 07 16; 373(3):220-31. PMID: 25981758; PMCID: PMC4764353.
      Citations:    
    117. Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA, Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax. 2016 Mar; 71(3):223-9. PMID: 25911223; PMCID: PMC4778725.
      Citations:    
    118. Flume PA, Aitken ML, Bilton D, Agent P, Charlton B, Forster E, Fox HG, Hebestreit H, Kolbe J, Zuckerman JB, Button BM, Flume PA, Aitken ML, Bilton D, Agent P, Charlton B, Forster E, Fox HG, Hebestreit H, Kolbe J, Zuckerman JB, Button BM. Optimising inhaled mannitol for cystic fibrosis in an adult population. Breathe (Sheff). 2015 Mar; 11(1):39-48. PMID: 26306102; PMCID: PMC4487380.
      Citations:    
    119. Thompson V, Mayer-Hamblett N, Kloster M, Bilton D, Flume PA, Thompson V, Mayer-Hamblett N, Kloster M, Bilton D, Flume PA. Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study. J Cyst Fibros. 2015 Sep; 14(5):632-8. PMID: 25725985; PMCID: PMC4549226.
      Citations:    
    120. Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, Morgan EE, VanDevanter DR, Flume PA, Stuart Elborn J, Geller DE, Conrad D, Aaron SD, Smyth AR, Fischer R, Kerem E, Bell SC, Loutit JS, Dudley MN, Morgan EE, VanDevanter DR, Flume PA. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros. 2015 Jul; 14(4):507-14. PMID: 25592656.
      Citations:    
    121. Bhattacharyya SB, Calado F, Priedane E, Shirore RM, Haworth CS, Flume PA, Sonathi V, Thomas SK, Bhattacharyya SB, Calado F, Priedane E, Shirore RM, Haworth CS, Flume PA, Sonathi V, Thomas SK. A De-Novo Economic Model to Assess Clinical and Economic Consequences of Bronchiectasis. Value Health. 2014 Nov; 17(7):A551. PMID: 27201797.
      Citations:    
    122. Flume PA, VanDevanter DR, Flume PA, VanDevanter DR. Clinical applications of pulmonary delivery of antibiotics. Adv Drug Deliv Rev. 2015 May; 85:1-6. PMID: 25453268; PMCID: PMC4406777.
      Citations:    
    123. Bradley JM, Koker P, Deng Q, Moroni-Zentgraf P, Ratjen F, Geller DE, Elborn JS, Bradley JM, Koker P, Deng Q, Moroni-Zentgraf P, Ratjen F, Geller DE, Elborn JS, Tiotropium Cystic Fibrosis Study Group. Testing two different doses of tiotropium Respimat? in cystic fibrosis: phase 2 randomized trial results. PLoS One. 2014; 9(9):e106195. PMID: 25188297; PMCID: PMC4154718.
      Citations:    
    124. Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J, Haas L, Lewis SA, Leitzinger S, Montgomery AB, McKevitt MT, Gossage D, Quittner AL, O'Riordan TG, Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J, Haas L, Lewis SA, Leitzinger S, Montgomery AB, McKevitt MT, Gossage D, Quittner AL, O'Riordan TG. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014 Sep; 2(9):738-49. PMID: 25154045.
      Citations:    
    125. Quittner AL, Marciel KK, Salathe MA, O'Donnell AE, Gotfried MH, Ilowite JS, Metersky ML, Flume PA, Lewis SA, McKevitt M, Montgomery AB, O'Riordan TG, Barker AF, Quittner AL, Marciel KK, Salathe MA, O'Donnell AE, Gotfried MH, Ilowite JS, Metersky ML, Flume PA, Lewis SA, McKevitt M, Montgomery AB, O'Riordan TG, Barker AF. A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis. Chest. 2014 Aug; 146(2):437-448. PMID: 24626872.
      Citations:    
    126. Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, Kashirskaya N, Munck A, Ratjen F, Schwarzenberg SJ, Sermet-Gaudelus I, Southern KW, Taccetti G, Ullrich G, Wolfe S, Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, Kashirskaya N, Munck A, Ratjen F, Schwarzenberg SJ, Sermet-Gaudelus I, Southern KW, Taccetti G, Ullrich G, Wolfe S, European Cystic Fibrosis Society. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros. 2014 May; 13 Suppl 1:S23-42. PMID: 24856775.
      Citations:    
    127. Hill AT, Flume PA, Hill AT, Flume PA. Lung clearance index. A potential quantitative tool to assess treatment response in bronchiectasis? Am J Respir Crit Care Med. 2014 Mar 01; 189(5):510-1. PMID: 24579835.
      Citations:    
    128. Orr RK, Hoehn JL, Col NF, Gilley SK, Stenbit AE, Pasek RC, Sas KM, Steele SL, Amria M, Bunni MA, Estell KP, Schwiebert LM, Flume P, Gooz M, Haycraft CJ, Yoder BK, Miller C, Pavlik JA, Turner GA, Sisson JH, Bell PD. Deletion of airway cilia results in noninflammatory bronchiectasis and hyperreactive airways. Am J Physiol Lung Cell Mol Physiol. 2014 Jan; 306(2):L162-9. PMID: 24213915; PMCID: PMC3920206.
      Citations:    
    129. Stenbit AE, Bullington WM, Heh JL, Flume PA, Stenbit AE, Bullington WM, Heh JL, Flume PA. Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring. J Cyst Fibros. 2013 Jul; 12(4):403-6. PMID: 23266092.
      Citations:    
    130. Orr RK, Hoehn JL, Col NF, Bilton D, Bellon G, Charlton B, Cooper P, De Boeck K, Flume PA, Fox HG, Gallagher CG, Geller DE, Haarman EG, Hebestreit HU, Kolbe J, Lapey A, Robinson P, Wu J, Zuckerman JB, Aitken ML, CF301 and CF302 Investigators. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros. 2013 Jul; 12(4):367-76. PMID: 23234802.
      Citations:    
    131. Döring G, Flume P, Heijerman H, Elborn JS, D?ring G, Flume P, Heijerman H, Elborn JS, Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012 Dec; 11(6):461-79. PMID: 23137712.
      Citations:    
    132. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE, Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordo?ez CL, Geller DE, VX 08-770-104 Study Group. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012 Sep; 142(3):718-724. PMID: 22383668; PMCID: PMC3435140.
      Citations:    
    133. Flume PA, Van Devanter DR, Flume PA, Van Devanter DR. State of progress in treating cystic fibrosis respiratory disease. BMC Med. 2012 Aug 10; 10:88. PMID: 22883684; PMCID: PMC3425089.
      Citations:    
    134. Aitken ML, Bellon G, De Boeck K, Flume PA, Fox HG, Geller DE, Haarman EG, Hebestreit HU, Lapey A, Schou IM, Zuckerman JB, Charlton B, Aitken ML, Bellon G, De Boeck K, Flume PA, Fox HG, Geller DE, Haarman EG, Hebestreit HU, Lapey A, Schou IM, Zuckerman JB, Charlton B, CF302 Investigators. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. 2012 Mar 15; 185(6):645-52. PMID: 22198974.
      Citations:    
    135. Flume PA, Flume PA. Chronic cystic fibrosis respiratory infections: where do we go from here? Introduction. Respir Med. 2011 Dec; 105 Suppl 2:S1. PMID: 22208545.
      Citations:    
    136. VanDevanter DR, Ballmann M, Flume PA, VanDevanter DR, Ballmann M, Flume PA. Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. Respir Med. 2011 Dec; 105 Suppl 2:S18-23. PMID: 22208544.
      Citations:    
    137. Lo D, VanDevanter DR, Flume P, Smyth A, Lo D, VanDevanter DR, Flume P, Smyth A. Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent? Respir Med. 2011 Dec; 105 Suppl 2:S9-17. PMID: 22208548.
      Citations:    
    138. Stenbit AE, Flume PA, Stenbit AE, Flume PA. Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2011 Nov; 17(6):442-7. PMID: 21881509.
      Citations:    
    139. Tomov SV, Flume PA, Stenbit AE, Ullian ME, Tomov SV, Flume PA, Stenbit AE, Ullian ME. Prerenal azotemia from excessive sweating in an adult with a cystic fibrosis gene mutation. Indian J Nephrol. 2011 Jul; 21(3):194-7. PMID: 21886981; PMCID: PMC3161439.
      Citations:    
    140. Flume PA, Flume PA. Pneumothorax in cystic fibrosis. Curr Opin Pulm Med. 2011 Jul; 17(4):220-5. PMID: 21460730.
      Citations:    
    141. Mogayzel PJ, Flume PA, Mogayzel PJ, Flume PA. Update in cystic fibrosis 2010. Am J Respir Crit Care Med. 2011 Jun 15; 183(12):1620-4. PMID: 21693717.
      Citations:    
    142. Geller DE, Flume PA, Griffith DC, Morgan E, White D, Loutit JS, Dudley MN, Geller DE, Flume PA, Griffith DC, Morgan E, White D, Loutit JS, Dudley MN. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother. 2011 Jun; 55(6):2636-40. PMID: 21444699; PMCID: PMC3101414.
      Citations:    
    143. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ, Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ, Mpex 204 Study Group. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011 Jun 01; 183(11):1510-6. PMID: 21471106.
      Citations:    
    144. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE, Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi G, He E, Geller DE. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011 Jan; 10(1):54-61. PMID: 21075062; PMCID: PMC4086197.
      Citations:    
    145. Flume PA, Mogayzel PJ, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC, Flume PA, Mogayzel PJ, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC, Clinical Practice Guidelines for Pulmonary Therapies Committee, Cystic Fibrosis Foundation Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010 Aug 01; 182(3):298-306. PMID: 20675678.
      Citations:    
    146. Mogayzel PJ, Flume PA, Mogayzel PJ, Flume PA. Update in cystic fibrosis 2009. Am J Respir Crit Care Med. 2010 Mar 15; 181(6):539-44. PMID: 20208039.
      Citations:    
    147. Barto TL, Flume PA, Barto TL, Flume PA. Treatment of pulmonary exacerbations in adult cystic fibrosis patients: a review. Hosp Pract (1995). 2010 Feb; 38(1):26-34. PMID: 20469621.
      Citations:    
    148. Flume PA, Flume PA. Smoothing the transition from pediatric to adult care: lessons learned. Curr Opin Pulm Med. 2009 Nov; 15(6):611-4. PMID: 19696678.
      Citations:    
    149. O'Sullivan BP, Flume P, O'Sullivan BP, Flume P. The clinical approach to lung disease in patients with cystic fibrosis. Semin Respir Crit Care Med. 2009 Oct; 30(5):505-13. PMID: 19760538.
      Citations:    
    150. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC, Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC, Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009 Nov 01; 180(9):802-8. PMID: 19729669.
      Citations:    
    151. Flume PA, Ciolino J, Gray S, Lester MK, Flume PA, Ciolino J, Gray S, Lester MK. Patient-reported pain and impaired sleep quality in adult patients with cystic fibrosis. J Cyst Fibros. 2009 Sep; 8(5):321-5. PMID: 19665944.
      Citations:    
    152. Lester MK, Flume PA, Lester MK, Flume PA. Airway-clearance therapy guidelines and implementation. Respir Care. 2009 Jun; 54(6):733-50; discussion 751-3. PMID: 19467161.
      Citations:    
    153. Flume PA, Flume PA. Pulmonary complications of cystic fibrosis. Respir Care. 2009 May; 54(5):618-27. PMID: 19393106.
      Citations:    
    154. Flume PA, Robinson KA, O'Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, White TB, Marshall BC, Flume PA, Robinson KA, O'Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, White TB, Marshall BC, Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009 Apr; 54(4):522-37. PMID: 19327189.
      Citations:    
    155. Ghegan MD, Wise SK, White DR, Flume PA, Bowman CM, Virella-Lowell I, Schlosser RJ, Ghegan MD, Wise SK, White DR, Flume PA, Bowman CM, Virella-Lowell I, Schlosser RJ. Cost-effective airway cultures in the cystic fibrosis patient. Am J Otolaryngol. 2009 May-Jun; 30(3):150-2. PMID: 19410117.
      Citations:    
    156. Flume PA, Stenbit A, Flume PA, Stenbit A. Making the diagnosis of cystic fibrosis. Am J Med Sci. 2008 Jan; 335(1):51-4. PMID: 18195584.
      Citations:    
    157. Stenbit A, Flume PA, Stenbit A, Flume PA. Pulmonary complications in adult patients with cystic fibrosis. Am J Med Sci. 2008 Jan; 335(1):55-9. PMID: 18195585.
      Citations:    
    158. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B, Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B, Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007 Nov 15; 176(10):957-69. PMID: 17761616.
      Citations:    
    159. Ford D, Flume PA, Ford D, Flume PA. Impact of lung transplantation on site of death in cystic fibrosis. J Cyst Fibros. 2007 Nov 30; 6(6):391-5. PMID: 17448734.
      Citations:    
    160. Woodworth BA, Ahn C, Flume PA, Schlosser RJ, Woodworth BA, Ahn C, Flume PA, Schlosser RJ. The delta F508 mutation in cystic fibrosis and impact on sinus development. Am J Rhinol. 2007 Jan-Feb; 21(1):122-7. PMID: 17283574.
      Citations:    
    161. Garwood S, Flume PA, Ravenel J, Garwood S, Flume PA, Ravenel J. Superior vena cava syndrome related to indwelling intravenous catheters in patients with cystic fibrosis. Pediatr Pulmonol. 2006 Jul; 41(7):683-7. PMID: 16703584.
      Citations:    
    162. Heaney DL, Flume P, Hamilton L, Lyon E, Wolff DJ, Heaney DL, Flume P, Hamilton L, Lyon E, Wolff DJ. Detection of an apparent homozygous 3120G>A cystic fibrosis mutation on a routine carrier screen. J Mol Diagn. 2006 Feb; 8(1):137-40. PMID: 16436646; PMCID: PMC1867569.
      Citations:    
    163. Sheridan MB, Fong P, Groman JD, Conrad C, Flume P, Diaz R, Harris C, Knowles M, Cutting GR, Sheridan MB, Fong P, Groman JD, Conrad C, Flume P, Diaz R, Harris C, Knowles M, Cutting GR. Mutations in the beta-subunit of the epithelial Na+ channel in patients with a cystic fibrosis-like syndrome. Hum Mol Genet. 2005 Nov 15; 14(22):3493-8. PMID: 16207733.
      Citations:    
    164. Flume PA, Strange C, Ye X, Ebeling M, Hulsey T, Clark LL, Flume PA, Strange C, Ye X, Ebeling M, Hulsey T, Clark LL. Pneumothorax in cystic fibrosis. Chest. 2005 Aug; 128(2):720-8. PMID: 16100160.
      Citations:    
    165. Flume PA, Yankaskas JR, Ebeling M, Hulsey T, Clark LL, Flume PA, Yankaskas JR, Ebeling M, Hulsey T, Clark LL. Massive hemoptysis in cystic fibrosis. Chest. 2005 Aug; 128(2):729-38. PMID: 16100161.
      Citations:    
    166. Flume P, Gray S, Bowman CM, Kerrigan C, Lester M, Virella-Lowell I, Flume P, Gray S, Bowman CM, Kerrigan C, Lester M, Virella-Lowell I. Emergency preparedness for the chronically ill. Am J Nurs. 2005 Mar; 105(3):68-72. PMID: 15729049.
      Citations:    
    167. Davé S, Honney S, Raymond J, Flume PA, Dav? S, Honney S, Raymond J, Flume PA. An unusual presentation of cystic fibrosis in an adult. Am J Kidney Dis. 2005 Mar; 45(3):e41-4. PMID: 15754262.
      Citations:    
    168. Lester MK, Flume PA, Gray SL, Anderson D, Bowman CM, Lester MK, Flume PA, Gray SL, Anderson D, Bowman CM. Nebulizer use and maintenance by cystic fibrosis patients: a survey study. Respir Care. 2004 Dec; 49(12):1504-8. PMID: 15571641.
      Citations:    
    169. Bosso JA, Flume PA, Gray SL, Bosso JA, Flume PA, Gray SL. Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2004 Jan; 48(1):281-4. PMID: 14693551; PMCID: PMC310170.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    170. Flume PA, Taylor LA, Anderson DL, Gray S, Turner D, Flume PA, Taylor LA, Anderson DL, Gray S, Turner D. Transition programs in cystic fibrosis centers: perceptions of team members. Pediatr Pulmonol. 2004 Jan; 37(1):4-7. PMID: 14679482.
      Citations: 13     Fields:    Translation:Humans
    171. Flume PA, Flume PA. Airway clearance techniques. Semin Respir Crit Care Med. 2003 Dec; 24(6):727-36. PMID: 16088588.
      Citations:    
    172. Douglas G, Bird K, Flume P, Silver R, Bolster M, Douglas G, Bird K, Flume P, Silver R, Bolster M. Wegener's granulomatosis in patients with rheumatoid arthritis. J Rheumatol. 2003 Sep; 30(9):2064-9. PMID: 12966617.
      Citations: 8     Fields:    Translation:Humans
    173. Flume PA, Flume PA. Pneumothorax in cystic fibrosis. Chest. 2003 Jan; 123(1):217-21. PMID: 12527625.
      Citations: 6     Fields:    Translation:Humans
    174. Silvestri GA, Sherman C, Williams T, Leong SS, Flume P, Turrisi A, Silvestri GA, Sherman C, Williams T, Leong SS, Flume P, Turrisi A. Caring for the dying patient with lung cancer. Chest. 2002 Sep; 122(3):1028-36. PMID: 12226050.
      Citations: 6     Fields:    Translation:Humans
    175. Flume PA, Flume PA. Medicinal treatment of intractable dyspnea in terminally ill patients. J S C Med Assoc. 2002 Aug; 98(4):196-9. PMID: 12216382.
      Citations:    Fields:    Translation:Humans
    176. Highland KB, Flume PA, Highland KB, Flume PA. A "story" of a woman with cystic fibrosis. Chest. 2002 May; 121(5):1704-7. PMID: 12006467.
      Citations:    Fields:    Translation:Humans
    177. Avendano CE, Flume PA, Silvestri GA, King LB, Reed CE, Avendano CE, Flume PA, Silvestri GA, King LB, Reed CE. Pulmonary complications after esophagectomy. Ann Thorac Surg. 2002 Mar; 73(3):922-6. PMID: 11899202.
      Citations: 62     Fields:    Translation:Humans
    178. Flume P, Klepser ME, Flume P, Klepser ME. The rationale for aerosolized antibiotics. Pharmacotherapy. 2002 Mar; 22(3 Pt 2):71S-79S. PMID: 11898884.
      Citations: 8     Fields:    Translation:Humans
    179. Kuhn RJ, Flume PA, Kuhn RJ, Flume PA. Treatment options for cystic fibrosis: case study and panel discussion. Pharmacotherapy. 2002 Mar; 22(3 Pt 2):86S-87S. PMID: 11898886.
      Citations:    Fields:    Translation:HumansCells
    180. Avendano CE, Flume PA, Baliga P, Lewin DN, Strange C, Reuben A, Avendano CE, Flume PA, Baliga P, Lewin DN, Strange C, Reuben A. Hepatopulmonary syndrome occurring after orthotopic liver transplantation. Liver Transpl. 2001 Dec; 7(12):1081-4. PMID: 11753911.
      Citations: 1     Fields:    Translation:Humans
    181. Anderson DL, Flume PA, Hardy KK, Anderson DL, Flume PA, Hardy KK. Psychological functioning of adults with cystic fibrosis. Chest. 2001 Apr; 119(4):1079-84. PMID: 11296173.
      Citations: 14     Fields:    Translation:Humans
    182. Benzo R, Flume PA, Turner D, Tempest M, Benzo R, Flume PA, Turner D, Tempest M. Effect of pulmonary rehabilitation on quality of life in patients with COPD: the use of SF-36 summary scores as outcomes measures. J Cardiopulm Rehabil. 2000 Jul-Aug; 20(4):231-4. PMID: 10955263.
      Citations: 19     Fields:    Translation:Humans
    183. Nichols PL, Flume P, Nichols PL, Flume P. Complications of cystic fibrosis in adults. J S C Med Assoc. 2000 Mar; 96(3):112-7. PMID: 10812878.
      Citations:    Fields:    Translation:Humans
    184. Bosso JA, Bonapace CR, Flume PA, White RL, Bosso JA, Bonapace CR, Flume PA, White RL. A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy. 1999 May; 19(5):620-6. PMID: 10331825.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    185. Flume PA, Flume PA. Cystic fibrosis: when to consider lung transplantation? Chest. 1998 May; 113(5):1159-61. PMID: 9596287.
      Citations: 2     Fields:    Translation:Humans
    186. Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA, Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. Comparative bactericidal activity of ceftazidime against isolates of Pseudomonas aeruginosa as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method. Antimicrob Agents Chemother. 1997 Nov; 41(11):2527-32. PMID: 9371361; PMCID: PMC164156.
      Citations: 3     Fields:    Translation:Cells
    187. Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA, Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 1997 Sep; 41(9):2053-6. PMID: 9303416; PMCID: PMC164067.
      Citations: 23     Fields:    Translation:HumansCells
    188. Flume PA, Flume PA. Current and novel therapies for cystic fibrosis. J S C Med Assoc. 1996 Sep; 92(9):381-8. PMID: 8854578.
      Citations:    Fields:    Translation:Humans
    189. Flume PA, Eldridge FL, Edwards LJ, Mattison LE, Flume PA, Eldridge FL, Edwards LJ, Mattison LE. Relief of the 'air hunger' of breathholding. A role for pulmonary stretch receptors. Respir Physiol. 1996 Mar; 103(3):221-32. PMID: 8738898.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    190. Flume PA, Eldridge FL, Edwards LJ, Houser LM, Flume PA, Eldridge FL, Edwards LJ, Houser LM. Relief of distress of breathholding: separate effects of expiration and inspiration. Respir Physiol. 1995 Jul; 101(1):41-6. PMID: 8525120.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    191. Judson MA, Flume PA, West DC, McFadden C, Crumbley AJ, Handy JR, Judson MA, Flume PA, West DC, McFadden C, Crumbley AJ, Handy JR. The MUSC lung transplantation program: the first year's experience. J S C Med Assoc. 1995 May; 91(5):223-7. PMID: 7776624.
      Citations:    Fields:    Translation:Humans
    192. Steinbach S, Sun L, Jiang RZ, Flume P, Gilligan P, Egan TM, Goldstein R, Steinbach S, Sun L, Jiang RZ, Flume P, Gilligan P, Egan TM, Goldstein R. Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis. N Engl J Med. 1994 Oct 13; 331(15):981-7. PMID: 7521938.
      Citations: 28     Fields:    Translation:HumansCells
    193. Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR, Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med. 1994 Jun; 149(6):1601-7. PMID: 7516251.
      Citations: 23     Fields:    Translation:HumansCells
    194. Flume PA, Egan TM, Westerman JH, Paradowski LJ, Yankaskas JR, Detterbeck FC, Mill MR, Flume PA, Egan TM, Westerman JH, Paradowski LJ, Yankaskas JR, Detterbeck FC, Mill MR. Lung transplantation for mechanically ventilated patients. J Heart Lung Transplant. 1994 Jan-Feb; 13(1 Pt 1):15-21; discussion 22-3. PMID: 7513185.
      Citations: 3     Fields:    Translation:HumansCells
    195. Flume PA, Eldridge FL, Edwards LJ, Houser LM, Flume PA, Eldridge FL, Edwards LJ, Houser LM. The Fowler breathholding study revisited: continuous rating of respiratory sensation. Respir Physiol. 1994 Jan; 95(1):53-66. PMID: 8153453.
      Citations: 10     Fields:    Translation:Humans
    196. Flume PA. test. View Publication.
    Flume's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (485)
    Explore
    _
    Co-Authors (56)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _